Biogen, Ionis: Nusinersen Meets Primary Endpoint At Interim Analysis Of Trial

Biogen Inc. (BIIB) and Ionis Pharmaceuticals, Inc. (IONS) said that nusinersen, their investigational treatment for spinal muscular atrophy or SMA, met the primary endpoint pre-specified for the interim analysis of Endear, the Phase 3 trial evaluating nusinersen in infantile-onset (consistent with Type 1) SMA.

from RTT - Biotech http://ift.tt/2abOVtG
via IFTTT